Business Wire

The newsfeed available here is provided by our content partner Business Wire. This is one of the most important and widest-reaching press services, providing news, press releases and multimedia content to the media, journalists and the public. Business Wire is a subsidiary of the Warren Buffett Group Berkshire Hathaway.
The NewsWire Hub ("X-Billboard") currently comprises four of the most important international news sources and is supplemented by a stock market information service. The individual newswire services complement each other and provide a complementary range of information, more than three quarters of the official news sources on which editors worldwide base their stock market reporting. Your advantage: You will find everything here in one overview. You can navigate to the individual sections using the control elements. In the terminal view, you can carry out individual searches at company level.
System-State: Number of processed items 20.839 Notifications successully processed since Inception
Business Wire is an important news source that can be accessed via the X-Billboard. It is part of the Newswire Hub, which bundles important international news sources for stock market participants in one central location. If you want to get a quick overview, you can easily scroll through the headlines. If you want to look at the news in more detail, you can use the detailed views of the info cards to directly access the respective news item and other analysis tools.
NEWS
EXPLORER
US14843C1053
State: 22.12.2024 | 6AM
Do you already know our new terminal view? Click here.
FIGI: BBG006YWVSR3
CSTL

Castle Biosciences, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Diagnostics & Research
NAME
Castle Biosciences, Inc.
ISIN
US14843C1053
TICKER
CSTL
MIC
XNAS
REUTERS
CSTL.OQ
BLOOMBERG
CSTL US
Thu, 19.12.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that on Dec. 13, 2024, the Compensation Committee of its Board of Directors granted restricted stock units (RSUs) to 135 employees covering an aggregate of 173,542 shares of common stock as an inducement material to...
Thu, 12.12.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new independent meta-analysis in Cancers assessing the efficacy of its DecisionDx-Melanoma test in predicting melanoma patient outcomes. The article, titled “The Prognostic Value of the 31-Gene ...
Wed, 20.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, Dec. 4, 2024, at 10:50 a.m. Eastern time. A live audio webcast of the C...
Tue, 19.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has been named a Houston Top Workplace for 2024 by the Houston Chronicle. This is the fourth consecutive year the Company has been ranked among the Houston metro area’s top workplaces. Castle also earned thr...
Fri, 08.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new data highlighting the clinical performance of its DecisionDx-Melanoma and MyPath Melanoma tests at the American Society of Dermatopathology (ASDP) 61st Annual Meeting, being held Nov. 7-10, in Chicago. “At Castle, w...
Thu, 07.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a significant milestone for the Company’s TissueCypher Barrett’s Esophagus test, which surpassed 25,000 test reports delivered since the Company acquired the test at the end of 2021. “At Castle, improving patient c...
Wed, 06.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the latest data from its prospective, multicenter DECIDE study exploring the impact of integrating DecisionDx-Melanoma test results into SLNB decision-making for patients recently diagnosed with melanoma. The update...
Mon, 04.11.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September 30, 2024. “We are thrilled with our third quarter performance, which reflects the continued success of our growth initiatives and the dedi...
Tue, 29.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating a significant reduction in healthcare management costs and an improvement in the quality of life for patients with Barrett’s esophagus (BE) whose management is guided by its TissueCypher test....
Mon, 28.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its executive management is scheduled to present a company overview at the following investor conferences next month: Guggenheim Securities Healthcare Innovation Conference on Nov. 11, 2024, at 2:30 p.m. East...
Sun, 20.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data supporting the clinical utility of its DecisionDx-Melanoma and DecisionDx-SCC tests in guiding risk-aligned treatment decisions, including SLNB for patients with melanoma and surveillance imaging for those ...
Wed, 16.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of two recent studies that provide further support for the clinical need of its MyPath® Melanoma gene expression profile (GEP) test, designed to aid in providing an accurate diagnosis for ambiguous m...
Mon, 14.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the third quarter and nine months ended Sept. 30, 2024, after the close of market on Monday, Nov. 4, 2024. Company management will host a conference call and webcast t...
Fri, 11.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will sponsor the 71st Annual Montagna Symposium on the Biology of the Skin, hosted by the Oregon Health & Science University (OHSU) Department of Dermatology and being held Oct. 17-21, 2024, in Stevenson...
Wed, 09.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will present new data related to its DecisionDx-Melanoma and DecisionDx®-UM tests for patients with cutaneous melanoma (CM) and uveal melanoma (UM), respectively, at the 21st International Congress of the So...
Wed, 02.10.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will hold a groundbreaking ceremony to celebrate the recent construction start of its new corporate campus and office building. The ceremony will take place on Oct. 22, 2024, at 10:00 a.m. Central time at th...
Fri, 27.09.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced new data demonstrating the ability of its DecisionDx-SCC test to provide clinically impactful risk stratification in high-risk SCC patient sub-populations (i.e., patients with suppressed immune systems in this study...
Mon, 23.09.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will present new data supporting the ability of its TissueCypher Barrett’s Esophagus test (TSP-9) to independently predict risk of progression to esophageal cancer in patients with Barrett’s esophagus (BE) at the American Foregut S...
Mon, 16.09.2024       Castle Biosciences

The Arizona Bioindustry Association, Inc. (AZBio) and Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that Kristen Oelschlager, R.N., Castle’s chief operating officer, has been named the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year. The award, prese...
Wed, 11.09.2024       Castle Biosciences

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced the publication of a new study further demonstrating that DecisionDx-Melanoma can precisely predict sentinel lymph node (SLN) positivity risk to help guide risk-aligned SLNB decisions, potentially reducing the numbe...

The information provided here is not subject to any editorial processing. It is prepared fully automatically and enriched with additional information and further research options. The aim of the content is to provide information seekers with the relevant information quickly and easily. A link back to the information provider and owner ensures that the data prepared here can be compared with the source information if required. The newsboard does not show information in real time. Please contact the exchange operator for this information if required. There is no claim to completeness. High availability cannot be guaranteed. If you notice any errors in the functionality, please let us know using the "Report a Bug" form below.

RAW DATA PROCESSING means that raw data is processed without changing the content. The data is supplemented to improve the interpretation of the information in terms of usability.

Note: The newswire crosslink panel in the upper area allows you to quickly and conveniently access additional sources of information. In the terminal view, the news is filtered at company level and enables targeted research.


On behalf of the trading community, we would like to thank the operators of the trading venues for providing information services.